v2.4.1.9
RFS Pharma, LLC Acquisition (Tables)
12 Months Ended
Dec. 31, 2014
Business Combinations [Abstract]
Schedule of purchase price consideration
Purchased in-process research and development
$
184,966
Net book value of tangible assets acquired
and liabilities assumed
(183
)
Goodwill
65,195
Deferred tax liability
(65,195
)
Total purchase price
$
184,783
X
- Definition
Schedule of purchase price consideration.
+ References
No definition available.
+ Details
Name:
cocp_ScheduleOfPurchasePriceAllocation1TableTextBlock
Namespace Prefix:
cocp_
Data Type:
nonnum:textBlockItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
us-gaap_BusinessCombinationsAbstract
Namespace Prefix:
us-gaap_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration